AbbVie Inc. (ABBV)

144.24 +0.09 (+0.06%) As of 12:00PM EST. Market open.

AbbVie Inc.

1 North Waukegan Road
North Chicago, IL 60064-6400
United States
847 932 7900
https://www.abbvie.com

Sector(s): Healthcare
Industry: Drug Manufacturers - General
Full-time employees: 50,000

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Richard A. Gonzalez	Chairman & CEO	6.95M	N/A	1954
Mr. Robert A. Michael	President & COO	4M	N/A	1970
Mr. Scott T. Reents	Executive VP & CFO	2.97M	N/A	1968
Dr. Azita Saleki-Gerhardt Ph.D.	Executive VP & COO	2.58M	N/A	1963
Mr. Jeffrey Ryan Stewart	Executive VP & Chief Commercial Officer	2.98M	2.78M	1969
Dr. Thomas J. Hudson M.D.	Senior VP of Research & Development and Chief Scientific Officer	N/A	N/A	1962
Ms. Elizabeth Shea	Senior Vice President of Investor Relations	N/A	N/A	N/A
Mr. Sanjay Narayan	VP, Chief Ethics & Compliance Officer	N/A	N/A	N/A
Ms. Tracie Haas	Senior Vice President of Corporate Responsibility, Brand & Communications	N/A	N/A	N/A
Mr. Timothy J. Richmond	Executive VP & Chief Human Resources Officer	1.12M	N/A	1966

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; Genentech, Inc.; and California Institute for Biomedical Research (Calibr). The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Corporate governance

AbbVie Inc.’s ISS governance QualityScore as of 1 December 2023 is 8. The pillar scores are Audit: 7; Board: 5; Shareholder rights: 9; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.